ID   PLCE1_RAT               Reviewed;        2281 AA.
AC   Q99P84;
DT   31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   29-MAY-2024, entry version 154.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 {ECO:0000305};
DE            EC=3.1.4.11 {ECO:0000269|PubMed:11179219};
DE   AltName: Full=Phosphoinositide phospholipase C-epsilon-1;
DE   AltName: Full=Phospholipase C-epsilon-1;
DE            Short=PLC-epsilon-1;
GN   Name=Plce1 {ECO:0000312|RGD:69424}; Synonyms=Plce;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, CATALYTIC ACTIVITY,
RP   ACTIVITY REGULATION, COFACTOR, INTERACTION WITH HRAS AND RAP1A, AND
RP   MUTAGENESIS OF LYS-2150 AND LYS-2152.
RC   TISSUE=Heart;
RX   PubMed=11179219; DOI=10.1093/emboj/20.4.743;
RA   Kelley G.G., Reks S.E., Ondrako J.M., Smrcka A.V.;
RT   "Phospholipase C(epsilon): a novel Ras effector.";
RL   EMBO J. 20:743-754(2001).
RN   [2]
RP   ACTIVITY REGULATION.
RX   PubMed=11641393; DOI=10.1074/jbc.c100574200;
RA   Wing M.R., Houston D., Kelley G.G., Der C.J., Siderovski D.P., Harden T.K.;
RT   "Activation of phospholipase C-epsilon by heterotrimeric G protein
RT   betagamma-subunits.";
RL   J. Biol. Chem. 276:48257-48261(2001).
RN   [3]
RP   ACTIVITY REGULATION.
RX   PubMed=11788587; DOI=10.1074/jbc.m109059200;
RA   Murphy G.A., Graham S.M., Morita S., Reks S.E., Rogers-Graham K.,
RA   Vojtek A., Kelley G.G., Der C.J.;
RT   "Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-
RT   Ras2-mediated transformation.";
RL   J. Biol. Chem. 277:9966-9975(2002).
RN   [4]
RP   ACTIVITY REGULATION, AND INTERACTION WITH RHOA.
RX   PubMed=12900402; DOI=10.1074/jbc.m306904200;
RA   Wing M.R., Snyder J.T., Sondek J., Harden T.K.;
RT   "Direct activation of phospholipase C-epsilon by Rho.";
RL   J. Biol. Chem. 278:41253-41258(2003).
RN   [5]
RP   FUNCTION.
RX   PubMed=12721365; DOI=10.1073/pnas.1031494100;
RA   Czyzyk J., Brogdon J.L., Badou A., Henegariu O., Preston Hurlburt P.,
RA   Flavell R., Bottomly K.;
RT   "Activation of CD4 T cells by Raf-independent effectors of Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6003-6008(2003).
RN   [6]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY REGULATION.
RX   PubMed=15322077; DOI=10.1074/jbc.m407111200;
RA   Seifert J.P., Wing M.R., Snyder J.T., Gershburg S., Sondek J., Harden T.K.;
RT   "RhoA activates purified phospholipase C-epsilon by a guanine nucleotide-
RT   dependent mechanism.";
RL   J. Biol. Chem. 279:47992-47997(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=16314422; DOI=10.1074/jbc.m507681200;
RA   Kelley G.G., Kaproth-Joslin K.A., Reks S.E., Smrcka A.V.,
RA   Wojcikiewicz R.J.H.;
RT   "G-protein-coupled receptor agonists activate endogenous phospholipase
RT   Cepsilon and phospholipase Cbeta3 in a temporally distinct manner.";
RL   J. Biol. Chem. 281:2639-2648(2006).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH IQGAP1.
RX   PubMed=17086182; DOI=10.1038/ng1918;
RA   Hinkes B., Wiggins R.C., Gbadegesin R., Vlangos C.N., Seelow D.,
RA   Nuernberg G., Garg P., Verma R., Chaib H., Hoskins B.E., Ashraf S.,
RA   Becker C., Hennies H.C., Goyal M., Wharram B.L., Schachter A.D.,
RA   Mudumana S., Drummond I., Kerjaschki D., Waldherr R., Dietrich A.,
RA   Ozaltin F., Bakkaloglu A., Cleper R., Basel-Vanagaite L., Pohl M.,
RA   Griebel M., Tsygin A.N., Soylu A., Mueller D., Sorli C.S., Bunney T.D.,
RA   Katan M., Liu J., Attanasio M., O'toole J.F., Hasselbacher K., Mucha B.,
RA   Otto E.A., Airik R., Kispert A., Kelley G.G., Smrcka A.V., Gudermann T.,
RA   Holzman L.B., Nuernberg P., Hildebrandt F.;
RT   "Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic
RT   syndrome variant that may be reversible.";
RL   Nat. Genet. 38:1397-1405(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1093, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: The production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated
CC       by activated phosphatidylinositol-specific phospholipase C enzymes.
CC       PLCE1 is a bifunctional enzyme which also regulates small GTPases of
CC       the Ras superfamily through its Ras guanine-exchange factor (RasGEF)
CC       activity. As an effector of heterotrimeric and small G-protein, it may
CC       play a role in cell survival, cell growth, actin organization and T-
CC       cell activation. In podocytes, is involved in the regulation of
CC       lamellipodia formation. Acts downstream of AVIL to allow ARP2/3 complex
CC       assembly (By similarity). {ECO:0000250|UniProtKB:Q9P212,
CC       ECO:0000269|PubMed:12721365, ECO:0000269|PubMed:16314422,
CC       ECO:0000269|PubMed:17086182}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-
CC         diacyl-sn-glycerol + H(+); Xref=Rhea:RHEA:33179, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17815, ChEBI:CHEBI:58456,
CC         ChEBI:CHEBI:203600; EC=3.1.4.11;
CC         Evidence={ECO:0000269|PubMed:11179219};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:11179219};
CC   -!- ACTIVITY REGULATION: Activated by the heterotrimeric G-protein subunits
CC       GNA12, GNA13 and GNB1-GNG2. Activated by HRAS, RAP1A, RHOA, RHOB, RHOC,
CC       RRAS and RRAS2. Activated by the G(s)-coupled GPCRs ADRB2, PTGER1 and
CC       CHRM3 through cyclic-AMP formation and RAP2B activation. Inhibited by
CC       G(i)-coupled GPCRs. {ECO:0000269|PubMed:11179219,
CC       ECO:0000269|PubMed:11641393, ECO:0000269|PubMed:11788587,
CC       ECO:0000269|PubMed:12900402, ECO:0000269|PubMed:15322077}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.0 uM for PtdIns(4,5)P2 {ECO:0000269|PubMed:15322077};
CC         Vmax=10 umol/min/mg enzyme {ECO:0000269|PubMed:15322077};
CC   -!- SUBUNIT: Interacts with RHOA (PubMed:12900402). Interacts with GTP-
CC       bound HRAS, RAP1A, RAP2A, RAP2B and RRAS (By similarity). Interacts
CC       with IQGAP1 (PubMed:17086182). Interacts with AVIL (By similarity).
CC       {ECO:0000250|UniProtKB:Q9P212, ECO:0000269|PubMed:12900402,
CC       ECO:0000269|PubMed:17086182}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q9P212}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q9P212}. Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:Q9P212}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:Q9P212}. Note=Recruited to plasma membrane by
CC       activated HRAS and RAP2. Recruited to perinuclear membrane by activated
CC       RAP1A. Isoform 1 and isoform 2 associates with Golgi membranes.
CC       {ECO:0000250|UniProtKB:Q9P212}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Detected in glomerular
CC       podocytes (at protein level). {ECO:0000269|PubMed:11179219,
CC       ECO:0000269|PubMed:17086182}.
CC   -!- DOMAIN: The Ras-associating domain 1 is degenerated and may not bind
CC       HRAS (By similarity). The Ras-associating domain 2 mediates interaction
CC       with GTP-bound HRAS, RAP1A and probably RAP2A and RAP2B and recruitment
CC       of HRAS to the cell membrane. {ECO:0000250}.
CC   -!- DOMAIN: The Ras-GEF domain has a GEF activity towards HRAS and RAP1A.
CC       Mediates activation of the mitogen-activated protein kinase pathway (By
CC       similarity). {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF323615; AAK06775.1; -; mRNA.
DR   RefSeq; NP_446210.1; NM_053758.2.
DR   PDB; 6PMP; X-ray; 2.73 A; A/B/C/D=1284-2098.
DR   PDBsum; 6PMP; -.
DR   AlphaFoldDB; Q99P84; -.
DR   SMR; Q99P84; -.
DR   BioGRID; 250398; 1.
DR   IntAct; Q99P84; 1.
DR   STRING; 10116.ENSRNOP00000072165; -.
DR   iPTMnet; Q99P84; -.
DR   PhosphoSitePlus; Q99P84; -.
DR   PaxDb; 10116-ENSRNOP00000062667; -.
DR   GeneID; 114633; -.
DR   KEGG; rno:114633; -.
DR   AGR; RGD:69424; -.
DR   CTD; 51196; -.
DR   RGD; 69424; Plce1.
DR   eggNOG; KOG0169; Eukaryota.
DR   InParanoid; Q99P84; -.
DR   OrthoDB; 2900494at2759; -.
DR   BRENDA; 3.1.4.11; 5301.
DR   Reactome; R-RNO-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   SABIO-RK; Q99P84; -.
DR   PRO; PR:Q99P84; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:RGD.
DR   GO; GO:0004629; F:phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IDA:RGD.
DR   GO; GO:0006651; P:diacylglycerol biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:RGD.
DR   GO; GO:0032835; P:glomerulus development; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IDA:RGD.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IBA:GO_Central.
DR   CDD; cd00275; C2_PLC_like; 1.
DR   CDD; cd16203; EFh_PI-PLCepsilon; 1.
DR   CDD; cd08596; PI-PLCc_epsilon; 1.
DR   CDD; cd17229; RA1_PLC-epsilon; 1.
DR   CDD; cd01780; RA2_PLC-epsilon; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 3.20.20.190; Phosphatidylinositol (PI) phosphodiesterase; 1.
DR   Gene3D; 1.10.840.10; Ras guanine-nucleotide exchange factors catalytic domain; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR046973; PLC-epsilon1_cat.
DR   InterPro; IPR028398; PLC-epsilon1_RA2.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR046974; PLC_epsilon1_EF.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000159; RA_dom.
DR   InterPro; IPR023578; Ras_GEF_dom_sf.
DR   InterPro; IPR001895; RASGEF_cat_dom.
DR   InterPro; IPR036964; RASGEF_cat_dom_sf.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR10336:SF6; 1-PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE PHOSPHODIESTERASE EPSILON-1; 1.
DR   PANTHER; PTHR10336; PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C FAMILY PROTEIN; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00788; RA; 1.
DR   Pfam; PF00617; RasGEF; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00314; RA; 1.
DR   SMART; SM00147; RasGEF; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF51695; PLC-like phosphodiesterases; 1.
DR   SUPFAM; SSF48366; Ras GEF; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50200; RA; 1.
DR   PROSITE; PS50009; RASGEF_CAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasm;
KW   Golgi apparatus; Guanine-nucleotide releasing factor; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Membrane; Metal-binding;
KW   Phosphoprotein; Reference proteome; Repeat; Transducer.
FT   CHAIN           1..2281
FT                   /note="1-phosphatidylinositol 4,5-bisphosphate
FT                   phosphodiesterase epsilon-1"
FT                   /id="PRO_0000256240"
FT   DOMAIN          528..781
FT                   /note="Ras-GEF"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00168"
FT   DOMAIN          1373..1521
FT                   /note="PI-PLC X-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   DOMAIN          1709..1825
FT                   /note="PI-PLC Y-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00271"
FT   DOMAIN          1830..1955
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          1991..2093
FT                   /note="Ras-associating 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00166"
FT   DOMAIN          2114..2217
FT                   /note="Ras-associating 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00166"
FT   REGION          1..68
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1050..1146
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1547..1572
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1664..1703
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1667..1743
FT                   /note="Required for activation by RHOA, RHOB, GNA12, GNA13
FT                   and G-beta gamma"
FT   REGION          2239..2281
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        24..38
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1054..1081
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1085..1122
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1127..1146
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1683..1703
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2239..2260
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1388
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   ACT_SITE        1433
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   MOD_RES         1093
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MUTAGEN         2150
FT                   /note="K->A: Inhibits binding to HRAS by 59% and
FT                   phospholipase stimulation by HRAS by 51%. Inhibits binding
FT                   to HRAS by 97% and phospholipase stimulation by HRAS by
FT                   86%; when associated with A-2152."
FT                   /evidence="ECO:0000269|PubMed:11179219"
FT   MUTAGEN         2150
FT                   /note="K->E: Inhibits binding to HRAS by 99% and
FT                   phospholipase stimulation by HRAS by 94%. Inhibits binding
FT                   to HRAS by 97% and phospholipase stimulation by HRAS by
FT                   94%; when associated with E-2152."
FT                   /evidence="ECO:0000269|PubMed:11179219"
FT   MUTAGEN         2152
FT                   /note="K->A: Inhibits binding to HRAS by 19% and
FT                   phospholipase stimulation by HRAS by 30%. Inhibits binding
FT                   to HRAS by 97% and phospholipase stimulation by HRAS by
FT                   86%; when associated with A-2150."
FT                   /evidence="ECO:0000269|PubMed:11179219"
FT   MUTAGEN         2152
FT                   /note="K->E: Inhibits binding to HRAS by 67% and
FT                   phospholipase stimulation by HRAS by 47%. Inhibits binding
FT                   to HRAS by 97% and phospholipase stimulation by HRAS by
FT                   94%; when associated with E-2150."
FT                   /evidence="ECO:0000269|PubMed:11179219"
FT   HELIX           1307..1318
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1324..1334
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1338..1341
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1342..1344
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1348..1356
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1361..1364
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1365..1367
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1373..1375
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1379..1381
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1382..1384
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1386..1389
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1392..1394
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1396..1399
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1404..1412
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1416..1422
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1443..1453
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1454..1456
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1462..1468
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1472..1486
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1487..1489
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1497..1500
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1501..1503
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1509..1514
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1516..1521
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1529..1541
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1621..1623
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1624..1627
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1628..1630
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1644..1647
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1651..1655
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1732..1734
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1735..1740
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1741..1750
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1752..1761
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1762..1767
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1781..1785
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1789..1793
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1800..1808
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1809..1814
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1816..1819
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1822..1824
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1830..1834
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1844..1846
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1848..1859
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1869..1878
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1879..1881
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1883..1886
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1894..1896
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1898..1908
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1910..1912
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1914..1921
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   TURN            1922..1925
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1926..1934
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1935..1937
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1940..1948
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1954..1967
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1978..1981
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           1985..1990
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          1991..1999
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          2001..2012
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           2017..2025
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          2038..2046
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          2059..2062
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   HELIX           2069..2073
FT                   /evidence="ECO:0007829|PDB:6PMP"
FT   STRAND          2078..2090
FT                   /evidence="ECO:0007829|PDB:6PMP"
SQ   SEQUENCE   2281 AA;  255393 MW;  7409A739B61F69EF CRC64;
     MTSEEMAASF LIPVPQRKVA SAQSVAEERG EKVSEAGIPK TRAGRQGGLT PRTISQRNEP
     EEESPRTDFS QVFSIARGEL DSDENHNERC WEENVPGSTK NHAVNCNSLL QSHQHALPPS
     QLCEVCDSVT EEHLCLQPGI PSPLERKVFP GIELEMEDSP MDVSPLGNQP GIMESSGPHS
     DRNMAVFHFH YAGDRTMPGA FHTLSEKFIL DDCANCVTLP GGQQNKNYMA YTCKLVELTR
     TCGSKNGQLK CDHCTSLRDE YLCFESSCRK AEALSSGGGF CEDGFTHGPS AKTFLNPLEE
     FSDNCEDVDD IFKGKKERST LLVRRFCKND REVKKSVYTG TRAIVRTLPS GHIGLAAWSY
     VDQKKAGLMW PCGNGMRPLS TVDVRQSGRQ RLSEAQWCLI YSAVRREETE DTVGSLLHCS
     TQLPTPDTAH GRIGDGPCLK QCVRDSECEY RATLQRTSIA QYITGSLLEA TTSLGARSSL
     LSSFGGSTGR IMLKERQPGT SMANSSPVPS SSAGISKELI DLQPLIQFPE EVASILTEQE
     QNIYRRVLPM DYLCFLTRDL SSPECQRSLP RLKACISESI LMSQSGEHNA LEDLVMRFNE
     VSSWVTWLIL TAGSMEEKRE VFSYLVHVAK CCWNMGNYNA VMEFLAGLRS RKVLKMWQFM
     DQSDIETMRS LKDAMAQHES SVEYKKVVTR ALHIPGCKVV PFCGVFLKEL CEVLDGASGL
     LKLCPRYSSQ EEALEFVADY SGQDNFLQRV GQNGLKNPEK ELTVNSIFQI IRSCSRSLET
     EDEESASEGS GSRKNSLKDK TRWQFIIGDL LDSDNDIFEK SKECDPHGSE ESQKAFDHGT
     ELIPWYVLSI QADVHQFLLQ GATVIHYDQD THLSARCFLQ LQPDNSTLTW MKPPTASPAG
     ARLKLGVLSN VAEPGKFPSL GNAGVSGLVE GILDLFSVKA VYMGHPGIDI HTVCVQNKLS
     SMLLSETGVT LLYGLQTTDN RLLHFVAPKH TAKMLFSGLL ELTTAVRKIR KFPDQRQQWL
     RKQYVSFYQE DGRYEGPTLA HAVELFGGRR WSTRNPSPGM SAKNAEKPNM QRNNTLGIST
     TKKKKKMLMR GESGEVTDDE MATRKAKMYR ECRSRSGSDP QEANEQEDSE ANVITNPPNP
     LHSRRAYSLT TAGSPNLATG MSSPISAWSS SSWHGRIKGG MKGFQSFMVS DSNMSFIEFV
     ELFKSFSIRS RKDLKDIFDI YSVPCNRSAS ESTPLYTNLT IEENTNDLQP DLDLLTRNVS
     DLGLFMKSKQ QLSDNQRQIS DAIAAASIVT NGTGIESTSL GIFGVGILQL NDFLVNCQGE
     HCTYDEILSI IQKFEPNISM CHQGLLSFEG FARFLMDKDN FASKNDESRE NKKDLQLPLS
     YYYIESSHNT YLTGHQLKGE SSVELYSQVL LQGCRSIELD CWDGDDGMPI IYHGHTLTTK
     IPFKEVVEAI DRSAFITSDL PIIISIENHC SLPQQRKMAE IFKSVFGEKL VAKFLFETDF
     SDDPMLPSPD QLRRKVLLKN KKLKAHQTPV DILKQKAHQL ASMQTQAFTG GNANPPPASN
     EEEEDEEDEY DYDYESLSDD NILEDRPENK SCADKLQFEY NEEVPKRIKK ADNSSGNKGK
     VYDMELGEEF YLPQNKKESR QIAPELSDLV IYCQAVKFPG LSTLNSSGSG RGKERKSRKS
     IFGNNPGRMS PGETASFNRT SGKSSCEGIR QIWEEPPLSP NTSLSAIIRT PKCYHISSLN
     ENAAKRLCRR YSQKLIQHTA CQLLRTYPAA TRIDSSNPNP LMFWLHGIQL VALNYQTDDL
     PLHLNAAMFE ANGGCGYVLK PPVLWDKSCP MYQKFSPLER DLDAMDPATY SLTIISGQNV
     CPSNSTGSPC IEVDVLGMPL DSCHFRTKPI HRNTLNPMWN EQFLFRVHFE DLVFLRFAVV
     ENNSSAITAQ RIIPLKALKR GYRHLQLRNL HNEILEISSL FINSRRMEDN PSGSTRPASL
     MFNTEERKCS QTHKVTVHGV PGPEPFAVFT INEGTKAKQL LQQILAVDQD TKLTAADYFL
     MEEKHFISKE KNECRKQPFQ RAVGPEEDIV QILNSWFPEE GYVGRIVLKP QQETLEEKNI
     VHDDREVILS SEEESFFVQV HDVSPEQPRT VIKAPRVSTA QDVIQQTLCK AKYSYSILNN
     PNPCDYVLLE EVMKDAPNKK SSTPKSSQRI LLDQECVFQA QSKWKGAGKF ILKLKEQVQA
     SREDKRRGIS FASELKKLTK STKQTRGLTS PPQLVASESV QSKEEKPMGA LASGDTAGYQ
     S
//
